WilmerHale Reps Apellis Pharmaceuticals in $60 Million Series E Financing

WilmerHale Reps Apellis Pharmaceuticals in $60 Million Series E Financing

News

On August 10, 2017, Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, announced the closing of a $60 million Series E preferred stock financing.

WilmerHale represented Apellis in this transaction, with a team led by Stuart Falber and included Mhairi Immermann and Alicia Lee.

Read Apellis' press release